OMEICOS Therapeutics is a biotechnology company focused on developing innovative therapies for cardiovascular, inflammatory, and mitochondrial diseases, which have high unmet medical needs. The company leverages its proprietary approach to target critical cell protective pathways and utilizes its industry-leading expertise in omega-3 fatty acid metabolism. OMEICOS's lead compound, OMT-28, has shown promising results and is a key part of their therapeutic pipeline. The company primarily serves the healthcare and pharmaceutical markets, aiming to provide advanced treatment options that address significant gaps in current medical therapies. OMEICOS operates on a business model that includes research and development, clinical trials, and partnerships with other biotech firms and pharmaceutical companies. Revenue is generated through licensing agreements, collaborations, and potential future sales of their therapeutic products.

Keywords: biotechnology, cardiovascular, inflammatory, mitochondrial, omega-3, cell protection, OMT-28, healthcare, pharmaceutical, therapies.